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SUMMARY
Etanercept and infliximab are novel biological agents targeted against tumour necrosis factor
alpha (TNFa), a key cytokine in the pathogenesis of rheumatoid arthritis (RA). We report the
results of their use over a two year period in 94 patients with severe inflammatory arthritis.
Eighty-eight adults with active inflammatory arthritis (82 with RA), unresponsive to all
conventional treatment, received biological therapy in one offive specialist centres in Northern
Ireland. 69 adult patients (78%) had a good response to treatment, four a partial response, and
seven no response. The results oftreatment could not be assessed in eight patients because they
hadonlyrecentlycommencedtherapy.Fourpatientshadamildallergicreactiontotreatmentbut
one patient developed fulminant lung fibrosis which may have been due to drug therapy and
eventually proved fatal. There were four cases ofmajor infection requiring hospitalisation. Two
patients responded to treatment, but one succumbed to bacterial pneumonia, and another to
bacterial meningitis. Six children with juvenile idiopathic arthritis (JIA) received etanercept.
Four achieved a good response, one a partial response, and one no response to treatment. This
study shows that the impressive response to anti-TNF therapies extends beyond the realm of
clinical trials to everyday clinical practice. These agents represent a major advance in the
treatment ofsevere inflammatory arthritis but they should be used with caution, particularly in
the elderly and in patients who are predisposed to infection.
INTRODUCTION
RA is a common disease (prevalence 0.5-1%),'
withatendencyforongoinginflammation, which
may lead to progressive joint destruction,
functionalimpairmentandhandicap.Spontaneous
remissions are rare and it is now known that
significant joint damage can occur within the
first two years of disease onset.2'3 Modern
management strategies stress the importance of
early diagnosis and treatment with disease
modifying anti-rheumatic drugs (DMARDs),
particularly methotrexate,whichisnowthe"gold
standard" by which other therapies arejudged.4
Despite this, a significant number of patients
(around 10%) fail to respond to conventional
DMARDs, either alone or in combination. Their
disease follows arelentless downhill course with
persistentjointinflammation anddamage. RA of
thisseveritycarriesasignificantmortality5which
is compounded by the need for regular
corticosteroid therapy in order to achieve some
quality of life.
The cytokine, TNFx, is produced by activated
macrophages, and has a central role in the
pathogenesis of RA with elevated TNFoc levels
found in affected Joints.6 It is also implicated in
anumberofotherinflammatorydiseasesincluding
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ankylosingspondylitis,psoriaticarthritis,juvenile
idiopathic arthritis, Behcet'sandCrohn'sdisease.
Infliximab and etanercept are the first of a new
class oftargetedmodifiers ofbiological response
toTNFoxwhichhavebeenlicensedforuseagainst
intractable rheumatoid arthritis. Infliximab
(Remicade) is a chimeric monoclonal antibody
whilst Etanercept (Enbrel) is a soluble TNF
receptor antagonist. Both drugs act to reduce the
effective levels of intra-articular TNFox.
Infliximabisadministeredbyintravenousinfusion
every 6-8 weeks and is given concurrently with
methotrexate (or azathioprine) to reduce the risk
of allergic reaction to the chimeric protein.
Etanercept is self-administered subcutaneously
twice a week. Both drugs have been shown to be
extremely effective in controlling active
rheumatoiddiseaseandretardingtheprogression
of joint damage when compared with
methotrexate,7-9 and etanercept has also been
shown to be effective in treating resistant JIA.'0
TheBritish SocietyforRheumatology (BSR) has
produced guidelines for the administration of
these drugs in the UK.'I To be considered for
these therapies patients must have active RA as
definedbytheDiseaseAssessmentScore(DAS) 12
- a validated composite score consisting of
weighted swollen and tenderjoint counts, ESR,
andpatientfunctionalvisualanaloguescale.They
mustalsohavefailedonatleasttwoconventional
DMARDS (including full doses of methotrexate
if tolerated). Contraindications to treatment
include active infection, malignancy within the
past 10 years, multiple sclerosis, severe heart
failure, an indwelling catheter and chronic leg
ulcers. There has been atrendtowards the earlier
use of these drugs, particularly in the USA, and
increasing evidence suggests that they are
effective in other inflammatory arthritides such
as ankylosing spondylitis and psoriatic
arthritis.'3' 14
METHODS
Detailedrecordswerekeptofallpatientsreceiving
anti-TNF therapy (infliximab or etanercept) for
inflammatory arthritis in Northern Ireland
between November 1999 and October 2001.
Response to treatment was assessed after three
months asdefinedbyBSRGuidelinesforpatients
withperipheraljointdisease(DAS scoreimproved
by> 1.2, ortotalDAS reduced to<3.2).Response
in ankylosing spondylitis patients was assessed
using ESR, CRPand BASDAI (BathAnkylosing
Spondylitis Disease Activity Index).'" Patients
were monitored at regular intervals throughout
the studyperiodforsignsofadversedrugreaction
or intercurrent illness.
RESULTS
88 adults (mean age 51 years, range 23-78; 65
female, 23 male) with inflammatory arthritis
received treatment in five specialist centres. All
had established, severe, active disease,
unresponsive to multiple conventional therapies.
66 patients were treated in Musgrave Park
Hospital, nine in Altnagelvin Area Hospital, five
in Craigavon Area Hospital, five in Antrim Area
Hospital, and three in the Ulster Hospital,
Dundonald (fig. 1). 82 patients had RA, four
ankylosing spondylitis, one psoriatic arthritis,
and one persistent juvenile arthritis. 52 patients
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Fig 1. Adult treatment numbers by location (n=88;
MPH=Musgrave Park Hospital, UHD=Ulster
Hospital Dundonald, CAH=Craigavon Area
Hospital, ALT=Altnagelvin Area Hospital,
ANT=Antrim Area Hospital).
received infliximab (59%), and 36 etanercept
(41%). 47 of the patients (53%) were taking
concomitant oral corticosteroids. Six children
(mean age 14, range 8-18, three male, three
female) with JIA received etanercept, all in
Musgrave Park Hospital.
63 of82 (76%) patients with RA achieved agood
response to treatment. Four (5%) had a partial
response (i.e. met DAS response criteria but
requiredintermittentintramuscularorintravenous
steroid therapy) and seven (9%) did notrespond.
Eight patients (10%) had not been on treatment
long enough (3 months) to be assessed (fig. 2).
Bothpatientswithpsoriaticarthritisandpersistent
juvenile arthritis achieved a good response
0 The Ulster Medical Society, 2002.
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Fig 2. Response to anti-TNF therapies in adults with
rheumatoid arthritis (n=82).
according to DAS scores and all patients with
ankylosing spondylitis achieved agood response
according to ESR, CRP and BASDAI scores.
Overall, 78% ofadults achieved agoodresponse,
5% apartial response and 8%no response. 9.% of
patients could not be assessed because they had
onlyrecently commenced treatment. There was a
trendtowardshigherresponseratesforinfliximab
and methotrexate (n=52, 42 (80%) responders)
compared with etanercept monotherapy (n=36,
27 (75%) responders) in all adults.
In the adult group, four minor allergic reactions
(5%) were reported. A fifth patient, receiving
infliximab (with methotrexate), developed acute
alveolitis, adult respiratory distress syndrome
andfulminantpulmonaryfibrosis. Sheeventually
died despite treatment in an intensive care unit
for seven weeks. There were four cases ofmajor
infection(5%),requiringhospital admission. One
patient, on infliximab (with azathioprine, not on
oral steroids), developed miliary tuberculosis.
This was isolated from sputum and urine after 12
weeks of treatment.
Pre-treatment chest X-Ray had been normal, and
there was no prior history or family history of
tuberculosis. Asecond, onetanercept,developed
probable septic arthritis in threejoints, although
an organism was not isolated as antibiotics had
beengivenpriortojointaspiration. Bothpatients
responded to appropriate antibiotic therapy. A
third patient, on etanercept, developed a middle
ear infection, which rapidly progressed to
pneumococcalmeningitis withbrainabscess, and
died after a protracted illness. A fourth patient,
also on etanercept, developed a severe lobar
pneumonia and died after a short illness. The
mean age of patients with major infections was
65years(range53-76). 18(20%) minorinfections
wererecorded,duringwhichbiologicaltreatment
was temporarily discontinued.
Treatment was withdrawn in 18 of 88 adult
patients (22%). The reasons forwithdrawal were
adverseevents(ninepatients),non-response (five
patients), other(unrelated) illness (two patients),
andotherreasons (twopatients) -one attempting
to conceive, one concerned about potential
adverse effects.
Six children with JIA received etanercept. Four
achieved a good response to treatment, one a
partial response and one no response. Treatment
was temporarily withdrawn in the partial
responderbecauseofanepisodeofgastroenteritis.
DISCUSSION
Inthiscohortof94patients, atleast78% ofadults
and 67% ofchildren with inflammatory arthritis
achieved agood response to anti-TNFtherapy as
defined by BSR response criteria. Although the
scoring systems used in Europe (DAS score) and
North America (American College of
Rheumatology (ACR) response criteria) differ
slightly, these results compare favourably with
large scale published trials where42% to 59% of
establishedRApatientsreceivinginfliximab(with
methotrexate)achievedanACR20response(20%
improvement in disease activity), and 72% of
early rheumatoid arthritis patients receiving
etanerceptachieved anACR 20response after 12
months of treatment.7-9 This confirms that the
efficacy of anti-TNF therapies extends beyond
trialconditionstoeverydayclinicalpractice. This
was further emphasised by the fact that many of
ourpatients were able to reduce or stop their oral
corticosteroids. These drugs therefore represent
amajoradvanceinthetreatmentofinflammatory
arthritis.
Both drugs were generally well tolerated with
80% ofadults and 75% ofchildren remaining on
treatment at the end of the study period. This
comparesfavourablywithconventionalDMARD
therapies. Infections were common, with minor
infection seen in one fifth of patients receiving
thesedrugs. Serious infections occurred in 5% of
our patients. Although this group of patients is
prone to infectious complications by nature of
their inflammatory condition, and use of
DMARDS and corticosteroids,5 it remains to be
seen whether this serious infection rate is higher
than would be seen in a group with similar
characteristics, but not receiving anti-TNF
therapy. Datafromtrialconditionswouldsuggest
that serious infection rates are similar in
established RA patients receiving methotrexate
C The Ulster Medical Society, 2002.
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alone (8%), compared with those receiving
methotrexate with infliximab (6%).8 A major
trial comparing etanercept alone with
methotrexate alone in early RA found no
differenceintherateofseriousinfectionsbetween
the groups (both less than 3%).9 The slightly
lower serious infection rate in this study may be
partly attributable to the fact that these patients
had early, rather than established, rheumatoid
disease. The BSR is compiling a registry on the
use of anti-TNF drugs with control groups not
receiving eitherdrug, which should allow amore
formalassessmentoftherelativeriskofinfectious
diseaseattributabletoanti-TNFtherapyinclinical
practice.1'
In our study the average age of patients who
developed serious infection was greater than in
thecohortas awhole(65 versus 51 years) andthis
has led to even greatercaution in the use ofthese
drugs in older patients, particularly those with
multiple co-morbidities. Serious infections
occurred with both etanercept and infliximab,
and seemed to progress rapidly. All patients
receiving potent immunosuppressives should be
educated about symptoms that might suggest
infection and should be encouraged to report
such symptoms to their doctor immediately and,
in the case of etanercept, stop administering the
drug until advice is received. All of our patients
areinstructedabouttherisksofsepsisbeforethey
start biological therapy and each is given an
information card (similar to the well-known
steroidcard)tocarryintheeventofanemergency.
This is particularly pertinent for patients self-
administering etanercept, where we have noticed
that a number of patients seem reluctant to stop
temporarily their injections in the presence of
minorinfection,becauseofaworryabouttheloss
of clinical effect.
The use of these drugs has significant resource
implications. Each drug costs approximately
£8000perpatientperyear, and treatment mustbe
continued long-term if it is to remain effective.
The additional demands on medical and nursing
staff must also be considered. Patient selection,
drug administration and ongoing safety
monitoring are all costly but essential parts of a
biological treatment programme. Nevertheless,
the benefits of these new therapies are such that
these costs can be fully justified in terms of the
recently given approval for the use ofetanercept
and infliximab in patients with severe RA, and
etanerceptinsevereJIA'6, 17inEnglandandWales.
Several other cytokine modulators are in
development at present, and one (Anakinra - an
interleukin 1 receptor antagonist) has recently
been licensed for the treatment of RA.'8 The
future is likely to see these compounds used
much earlier in the course of the disease and in
variouscombinations. TheACRnowrecommends
consideringtheuseofbiological agents ifthereis
ongoing rheumatoid disease activity after three
months of full dose methotrexate therapy.19
Combinations ofbiological agents whichworkat
differentpoints intheinflammatorycascade may
ultimatelymaketheinductionofdiseaseremission
a realistic prospect.
Inconclusion, ourexperienceinNorthernIreland
over a two year period has confirmed that the
anti-TNF therapies, etanercept and infliximab,
represent a significant advance in the treatment
ofsevere RA and JIA. They are also ofbenefit in
other inflammatory arthritides such as psoriatic
arthritis and ankylosing spondylitis. Adverse
events in this cohort were not uncommon, and
there were a number of serious infections in our
patients (5%). These sometimes occurredrapidly
andwithlittlewarning. Wethereforerecommend
thatthesedrugsbeadministeredonlyinspecialist
centres to carefully selected patients. Our
experience confirms theneedforcarefulongoing
safety monitoring of these patients.
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potential prevention of long-term joint damage
and disability. It is not surprising therefore, that
the National Institute ofClinical Excellence has
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